Assignee
POXEL SA
FR·12 granted patents·7 pending applications·5 citations·filing 2017–2025
Top patents by PatentIndex Score
19 records- 0188US11123336B25-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the samePOXEL SA·Filed 2019·Granted Sep 21, 2021·2 cites·21 claims
- 0285US10940143B2Deuterium-enriched pioglitazonePOXEL SA·Filed 2019·Granted Mar 9, 2021·1 cites·8 claims
- 0383US10265305B25-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the samePOXEL SA·Filed 2017·Granted Apr 23, 2019·2 cites·9 claims
- 0478US11918569B25-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the samePOXEL SA·Filed 2021·Granted Mar 5, 2024·0 cites·28 claims
- 0577US11918567B2Deuterium-enriched pioglitazonePOXEL SA·Filed 2021·Granted Mar 5, 2024·0 cites·9 claims
- 0676US2025268879A1Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2025·Application pending·0 cites
- 0773US11141411B2Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2018·Granted Oct 12, 2021·0 cites·18 claims
- 0873US2022193055A1Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2021·Application pending·0 cites
- 0968US10576071B2Deuterium-enriched pioglitazonePOXEL SA·Filed 2018·Granted Mar 3, 2020·0 cites·10 claims
- 1067US2022362220A15-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using samePOXEL SA·Filed 2020·Application pending·0 cites
- 1166US2020253937A15-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using samePOXEL SA·Filed 2019·Application pending·0 cites
- 1264US11319313B2Crystalline forms of deuterium-enriched pioglitazonePOXEL SA·Filed 2021·Granted May 3, 2022·0 cites·14 claims
- 1362US2023074827A1Crystalline forms of deuterium-enriched pioglitazonePOXEL SA·Filed 2022·Application pending·0 cites
- 1461US2020239457A15-deutero-thiazolidinyldione compounds and methods of treating medical disorders using samePOXEL SA·Filed 2019·Application pending·0 cites
- 1560US12036226B2Methods of treating subjects having diabetes with chronic kidney diseasePOXEL SA·Filed 2022·Granted Jul 16, 2024·0 cites·20 claims
- 1660US11617754B2Methods of treating heart failure with preserved ejection fractionPOXEL SA·Filed 2018·Granted Apr 4, 2023·0 cites·22 claims
- 1760US2020390753A1Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disordersPOXEL SA·Filed 2019·Application pending·0 cites
- 1855US11767317B1Methods of synthesizing enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2021·Granted Sep 26, 2023·0 cites·20 claims
- 1953US11266652B2Methods of treating subjects having diabetes with chronic kidney diseasePOXEL SA·Filed 2020·Granted Mar 8, 2022·0 cites·20 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →